CD38, A Target for Immunotherapeutic Approaches in Cancer
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease:
-Flow-Cytometry-NB500-510-img0011.jpg "CD38 Antibody (HIT2) - BSA Free (NB500-510): Novus Biologicals")
CD38 Antibody (HIT2) - BSA Free (NB500-510): Novus Biologicals
CD38 affects the biological behavior and energy metabolism of nasopharyngeal carcinoma cells
Targeting CD38-dependent NAD+ metabolism to mitigate multiple organ fibrosis - ScienceDirect
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma | Journal for ImmunoTherapy of Cancer
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma - ScienceDirect
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Co-Expression of Positive Activation Marker CD38 and Negative or Exhaustion Marker PD-1 in CD8+ T Cells | Biocompare.com Kit/Reagent Review
CD38 at the junction between prognostic marker and therapeutic target: Trends in Molecular Medicine
Cells | Free Full-Text | CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy | HTML
CD38 - Wikipedia
CD38 and Regulation of the Immune Response Cells in Cancer
IJMS | Free Full-Text | Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE
CD38, A Target for Immunotherapeutic Approaches in Cancer
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide | Haematologica
New Strategies for Targeting CD38 in Multiple Myeloma Take Root
Frontiers | CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
International Clinical Cytometry Society
Frontiers | CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions
Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems
CD38-expressing macrophages drive age-related NAD+ decline | Nature Metabolism
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
